RUBRA MEDICAMENTS LTD. - 531099 - Closure of Trading Window
Pursuant to the Company''s Securities Dealing Code, the Trading Window for dealing in the Company''s Equity Shares will remain closed from Saturday, January 1, 2022 for all Designated Employees of the Company. The closure is in connection with the declaration of financial results of the Company for the quarter ending December 31, 2021. RUBRA MEDICAMENTS LTD. - 531099 - Newspaper Publication Of Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2021
Newspaper publication of Unaudited Financial Results for the quarter and half year ended September 30, 2021 RUBRA MEDICAMENTS LTD. - 531099 - Disclosure Of Related Party Transactions For The Half Year Ended September 30, 2021
Disclosure of Related Party Transactions for the half year ended September 30, 2021 RUBRA MEDICAMENTS LTD. - 531099 - Standalone Unaudited Financial Results Along With Limited Review Report, Asset And Liability Statement And Cash Flow Statement Of The Company For The Quarter And Half Year Ended September 30, 2021
Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the quarter and half year ended September 30, 2021 RUBRA MEDICAMENTS LTD. - 531099 - Board Meeting Intimation for The Meeting Of Board Of Directors Of The Company Will Be Held On November 11, 2021
RUBRA MEDICAMENTS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve Standalone Unaudited Financial Results along with limited review report, Asset and liability statement and Cash Flow Statement of the Company for the half year ended September 30, 2021. RUBRA MEDICAMENTS LTD. - 531099 - Shareholding for the Period Ended September 30, 2021
Rubra Medicaments Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here RUBRA MEDICAMENTS LTD. - 531099 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Abha KapoorDesignation :- Managing Director / Whole Time Director RUBRA MEDICAMENTS LTD. - 531099 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Rubra Medicaments Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here RUBRA MEDICAMENTS LTD. - 531099 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report RUBRA MEDICAMENTS LTD. - 531099 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM